Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This first-in-human study aims to establish the maximum tolerated dose of PG545 and to
evaluate its safety in subjects with advanced solid tumours. In addition the study will
explore whether PG545 exposure results in changes to chemicals produced by the body that are
associated with cancer growth and spread.
Phase:
Phase 1
Details
Lead Sponsor:
Progen Pharmaceuticals Zucero Pty Ltd
Collaborators:
Datapharm Australia Pty Ltd Statistical Revelations Pty Ltd